Meyka Pro banner
Cellyan Biotechnology Co., Ltd

Cellyan Biotechnology Co., Ltd (HKPD) Stock Competitors & Peer Comparison

See (HKPD) competitors and their performances in Stock Market.

HKPDNASDAQ
HealthcareMedical - Pharmaceuticals
$0.39
$0.01(3.68%)
U.S. Market is Open · 12:52

Peer Comparison Table: Medical - Pharmaceuticals Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
HKPD$0.38-11.73%4.2M-6.33-$0.06N/A
RPRX$58.18-0.60%25B11.48$5.07+1.56%
WBA$11.98+0.50%10.4B-1.64-$7.29+4.17%
CORT$90.52+0.89%9.7B258.63$0.35N/A
LQDA$79.94+6.20%7.1B571.00$0.14N/A
KNSA$63.95+4.65%4.8B71.06$0.90N/A
VCRE$11.82+1.03%3.3BN/AN/AN/A
TRLV$8.79+4.52%1.5B-20.88-$0.42N/A
HROWL$25.61+0.19%1.4BN/AN/AN/A
HROWM$26.03-0.08%1.3BN/AN/AN/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

HKPD vs RPRX Comparison July 2026

HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HKPD stands at 4.2M. In comparison, RPRX has a market cap of 25B. Regarding current trading prices, HKPD is priced at $0.38, while RPRX trades at $58.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HKPD currently has a P/E ratio of -6.33, whereas RPRX's P/E ratio is 11.48. In terms of profitability, HKPD's ROE is -0.14%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, HKPD is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for HKPD.Check RPRX's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions